arrow
A

Alice T. Shaw

massachusetts general hospital cancer center
H指数:115
被引数:7.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non–small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors

ALK阳性转移性非小细胞肺癌患者接受一线ALK酪氨酸激酶抑制剂治疗后,脑转移的实世界发病率、患病率及临床影响。

2025-11-280
PRE
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer

简明语言总结: 劳拉替尼与克唑替尼在非小细胞肺癌中的CROWN研究的5年结果

2024-10-030
OAAI
Therapy-induced APOBEC3A drives evolution of persistent cancer cells

治疗诱导的APOBEC3A驱动持续性癌细胞的进化

Nature
IF48.5
2023-07-050
PRE
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer

CROWN研究更新结果的通俗解读:在晚期非小细胞肺癌患者中,洛拉替尼与克唑替尼的对比

2023-06-120
OA
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
2023-04-0656
OAAI
Immunoproteasome expression and checkpoint blockade response in advanced non-small cell lung cancer
2023-04-040
PRE
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

晚期ALK阳性非小细胞肺癌患者中,一线劳拉替尼对比克唑替尼的疗效与安全性:3期随机、开放标签CROWN研究数据的更新分析

2023-04-01111
PRE
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
2022-03-0120
OAAI
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs

洛拉替尼对先前接受第二代ALK TKIs治疗的ALK阳性非小细胞肺癌患者的颅内和颅外疗效

2021-05-0174
OA
BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency
2020-09-1538
OAAI